Hinge Health, Inc.
NYSE:HNGEMedical - Healthcare Information Services
-$0.24 today
- Market cap
- $9.31B
- Beta
- 1.99
- P/E (TTM)
- -10.3
- EPS (TTM)
- -$6.49
Volume 1.23M
Average 1.34M
HNGE Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Hinge Health, Inc.NYSE: HNGE
Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Financing cash flow dips below year-ago levels
Q2 FY2026 financing cash flow of $30.48M (cash outflow) fell 59.7% year over year, behind the +201.2% change in trailing-twelve-month financing cash flow. Sequentially, it fell 73.0% from the prior quarter.
Context
- Financing cash flow amounted to 25.6% of revenue in FY2025, up 25.0 pp from a year earlier.
- Financing cash flow grew in size in 1 of the last 2 fiscal years.
- FY2025 was the largest annual figure in the 3 fiscal years shown.
What to watch
Whether quarterly growth recovers from -59.7% toward the trailing-twelve-month pace of +201.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (150.47M) USD
- Year-over-year change
- -6733.2%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (150.47M) | -6733.2% |
| FY2024 | 2024-12-31 | (2.2M) | +26.6% |
| FY2023 | 2023-12-31 | (3M) | — |
Financing Cash Flow vs competitors
How HNGE compares with its peers on the latest reported figures
- HNGE's LTM Jun 2026 financing cash flow of $222.34M is the 2nd largest of the 5 companies compared; the peer median is $50.98M.
- Its year-over-year change of +201.2% is the 3rd highest of 5, against a peer median of +507.5%.
- Financing cash flow amounts to 30.9% of revenue for HNGE, versus a peer median of 9.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | $955M | +1010.5% | +1.0% | 15.5% | |
| LTM Jun 2026 | $222.34M | +201.2% | — | 30.9% | |
| LTM Mar 2026 | $135.97M | +9861.1% | +101.4% | 48.0% | |
| LTM Apr 2026 | $77.57M | -331.7% | -51.7% | 3.4% | |
| LTM Mar 2026 | $24.4M | +4.5% | — | 3.3% | |
| Peer median (excluding HNGE) | $50.98M | +507.5% | +1.0% | 9.4% | |
Competitors are the stored peer set for HNGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Net Income | (108.14M) | (11.93M) | (528.26M) |
| Depreciation & Amortization | 5.63M | 5.95M | 5.13M |
| Deferred Income Tax | (473K) | (585K) | 53K |
| Stock-Based Compensation | 1.65M | 739K | 643.01M |
| Change in Working Capital | 9.41M | 13.5M | (2.01M) |
| Accounts Receivables | (23.13M) | (1.34M) | (26.63M) |
| Inventory | 10.57M | 608K | (4.76M) |
| Accounts Payables | 0 | (10.98M) | 29.41M |
| Other Working Capital | 21.97M | 25.21M | (31K) |
| Other Non-Cash Items | 28.02M | 41.33M | 53.52M |
| Operating Cash Flow | (63.91M) | 49M | 171.44M |
| Capital Expenditures | (4.62M) | (3.77M) | (708K) |
| Acquisitions (Net) | 0 | 0 | (4M) |
| Purchases of Investments | (453.34M) | (324.54M) | (472.29M) |
| Sales of Investments | 459.45M | 346.63M | 368.59M |
| Other Investing Activities | (2.64M) | (2.73M) | (5.36M) |
| Investing Cash Flow | 1.5M | 18.31M | (113.76M) |
| Debt Repayment | 0 | 0 | 0 |
| Common Stock Issued | 0 | 610K | 265.2M |
| Common Stock Repurchased | 0 | 0 | (65.03M) |
| Dividends Paid | 0 | 0 | 0 |
| Other Financing Activities | (3M) | (2.81M) | (350.64M) |
| Financing Cash Flow | (3M) | (2.2M) | (150.47M) |
| Effect of Forex Changes | 0 | 0 | 0 |
| Net Change in Cash | (65.41M) | 65.11M | (92.79M) |
| Free Cash Flow | (68.52M) | 45.23M | 170.73M |
Hinge Health, Inc.
NYSE:HNGE
Intrinsic Alpha fair value
Locked
Current Price
$114.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.